Vanderson Rocha, 2, 17 and Eliane Gluckman 2, 18 BACKGROUND: Techniques for banking cord blood units (CBUs) as source for hematopoietic stem cell transplantation have been developed over the past 20 years, aimed to improve laboratory efficiency without altering the biologic properties of the graft. A large-scale, registry-based assessment of the impact of the banking variables on the clinical outcome is currently missing.
STUDY DESIGN AND METHODS:
A total of 677 single cord blood transplants (CBTs) carried out for acute leukemia in complete remission in centers affiliated with the European Society for Blood and Marrow Transplantation were selected. An extensive set of data concerning CBU banking were collected and correlations with clinical outcome were assessed. Clinical endpoints were transplant-related mortality, engraftment, and graftversus-host disease (GVHD).
RESULTS:
The median time between collection and CBT was 4.1 years (range, 0.2-16.3 years). Volume reduction (VR) of CBUs before freezing was performed in 59.2% of available reports; in half of these the frozen volume was less than 30 mL. Cumulative incidences of neutrophil engraftment on Day 60, 100-day acute GVHD (II-IV), and 4-year chronic GVHD were 87, 29, and 21 6 2%. The cumulative incidence of nonrelapse mortality (NRM) at 100 days and 4-year NRM were, respectively, 16 6 2 and 30 6 2%. Neither the variables related to banking procedures nor the interval between collection and CBT influenced the clinical outcome.
CONCLUSION: These findings indicate a satisfactory validation of the techniques associated with CBU VR across the banks. Cell viability assessment varied among the banks, suggesting that efforts to improve the standardization of CBU quality controls are needed. Favorable initial results of related cord blood transplantation (CBT), including a lower rate of acute and chronic graft-versus-host disease (GVHD) when compared to other sources of HSCs, 2 led to the creation of unrelated CB banks after 1992. [3] [4] [5] Due to both the availability of a large inventory of cord blood units (CBUs) and the improvement of transplant technology, the number of transplants using this source of stem cells increased significantly (Eurocord, personal communication). Collection of CB is usually performed in a maternity unit linked to a cord blood bank (CBB). All other procedures (characterization, processing, freezing, and storage of the CBU) are performed at the bank. Thus, success of a CBT is strongly dependent on the quality of the CBB activity. 6, 7 The definition of "high-quality units" is generally referred to large-size units that contain a high number of hematopoietic progenitors to ensure faster engraftment. However, the concept of quality in CB banking generally refers to the consistency of the CBU data reported by the banks to the registries. Discrepancies between CBU data reported by the bank and transplant center have been reported, which could possibly affect the selection of the most suitable CBU and therefore clinical outcomes. 8 Such discrepancies may also result from the variability of manipulation and the CBU characterization practice after thawing at transplant centers. 9, 10 Despite the development of CB banking standards and accreditation programs, a large variability in laboratory techniques still exists, with special reference to CBU characterization and volume reduction (VR). The latter represents a major issue for any allogeneic CBB as the low probability of a CBU being released results in a waste of cryogenic space and operational costs. 11 
MATERIALS AND METHODS

Study design
Major variables associated with the banking process, from collection to release, were listed. Only single CBU transplants were selected to avoid the overlapping of graft variables of multiple units. The inclusion criteria of transplant recipients focused on variables related to the quality of the banking process; therefore, patients with the same diagnosis (acute leukemia) and disease status (complete remission [CR]) at CBT were selected. TNC number at freezing !3310 7 is associated with a better engraftment rate and overall survival (OS) 15, 16 and therefore was selected as the minimum threshold for inclusion in this study. CBTs carried out between 1997 and 2010 were included, so as to be able to provide an adequate followup. Other cellular variables, such as CD341 cell count and colony-forming units were not universally performed, especially in the older units, and therefore they were not considered mandatory data for inclusion in this study. A (continued from previous page)
negative impact of the degree of HLA disparity was reported on both engraftment and nonrelapse mortality (NRM); 17 however, in the single-unit transplant setting, a disparity of not more than two of six HLA-A,B and DRB1 antigens is generally accepted. Therefore, the selection criteria for this analysis included patients with acute leukemias in any CR who had undergone a single unmanipulated CBT from an unrelated donor in EBMT centers. Further inclusion criteria were TNC at cryopreservation of at least 3 3 10 7 /kg and HLA-A,B (HLA typing at antigen level) and DRB1 (HLA typing at allele level) disparity of not more than two of six. Patients were classified as pediatric when their age was not more than 18 years. A minimum data set was also considered mandatory for inclusion in the study, such as follow-up with complete outcome data and bank identification.
Banking variables
Most banks did not concentrate the CBUs at the beginning of their activity and this started at a later stage; others began using one method and then switched to another. Indeed, concentration may well have been started with a manual method and subsequently carried out with an automated method. Therefore, we focused this study on the laboratory process instead of analyzing differences among individual banks.
The following variables of the banking process and disease and transplant characteristics were analyzed: VR of the CBU before cryopreservation, time interval between collection of the CBU and transplantation, recipient's age at CBT (adult vs. pediatric patients), diagnosis (myeloid vs. lymphoid leukemia), disease status at CBT, intensity of the conditioning regimen (reducedintensity conditioning [RIC] vs. myeloablative conditioning [MAC] that was defined as regimens containing either total body irradiation with a dose of >6 Gy or busulfan with a dose of >6.4 mg/kg intravenous [8 mg/ kg if oral] degree of HLA matching (number of mismatched HLA, defined as HLA-A,B by low-resolution typing and DRB1 high-resolution typing), cryopreserved TNCs (reported as 10 7 /kg recipient weight), and cytomegalovirus (CMV) status of the patient. The primary endpoint of this study was 100-day NRM. Secondary endpoints were neutrophil engraftment, acute and chronic GVHD rate, OS, and leukemia-free survival (LFS). The review board of Eurocord/EBMT approved this study.
Data search
Patients fulfilling the above inclusion criteria were selected from the Eurocord database. An invitation letter to participate in the study was sent to the banks that released CBU for transplant. Eurocord bank data collection forms were modified to integrate a larger set of laboratory variables. Data already reported to Eurocord were extracted and included in the updated data forms. All the banks that agreed to participate in the study received a form that only reported the selected patients' data. The list of participating banks is reported in Table S1 (available as supporting information in the online version of this paper).
Outcome definitions
The secondary endpoint of the study was neutrophil recovery, which was defined as achieving absolute neutrophil count of at least 0.5 3 10 9 /L for 3 consecutive days. The diagnosis and grading of acute and chronic GVHD was assigned by the transplantation center using standard criteria. 18 Relapse and death from any cause were considered events. NRM was defined as death without prior relapse. LFS was calculated from the date of CBT until death, relapse, or last disease-free follow-up. OS was calculated from the date of CBT until death or last observation alive.
Statistical analysis
The 
CBU characteristics
The median interval between CBU collection and transplant was 4.1 years (range, 0.2-16.3 years). Volume at collection (Fig. 1A) to the increasing use of concentrating the graft (Fig. 1B) ; overall the median (range) cryopreserved volume was 61 (10-430) mL. DMSO was the cryoprotectant used in all CBUs included in this analysis; data about the storage phase were available in 477 CBUs, being in liquid phase in 451 (94.5%) of them.
QCs at release
Control of the CBU identity at release on a reference sample is considered mandatory in the FACT-NetCord standards (4th Edition, 2010). A question about QC on cell viability in thawed CBU-associated samples was included in this survey and was reported to be carried out in 345 units. The most frequently reported methods included trypan blue (30.9%), 7-actinomycin-D (21.2%), and acridine orange (28.8%). The reported percent viabilities after thawing (mean 6 SD) were 79.9 6 17.2, 62.5 6 22.8, and 89.5 6 9, respectively. 
VR and outcomes
A VR of the CBU before freezing was reported in 401 (59.2%) of the 677 selected transplants. The procedure was not routinely applied in the early years of banking; therefore, transplants carried out with volume-reduced CBUs have become frequent in more recent years, resulting in some differences between the two groups. Table 1 summarizes the characteristics of this subset of patients: overall, unmanipulated CBUs were used earlier and in younger patients, containing less TNCs/kg patient's body weight, with a better HLA matching and in a more advanced phase of disease. A further analysis was carried out in concentrated units (i.e., those with VR), according to the extent of CBU volume before freezing ( 30 mL vs. >30 mL). VR below 30 mL was almost always (97%) achieved by adding HES as the sedimenting agent.
Results of univariate analysis are showed in Table 2 . VR at any level was not associated with outcomes, either in univariate or in multivariate analysis (Fig. 2) .The 60-day cumulative incidence of neutrophil engraftment was 87 6 1%. In multivariate analysis (Table 3) , patients receiving TNCs of at least 5.86 3 10 7 /kg presented a higher probability of neutrophil engraftment (hazard ratio [HR], 1.57; 95% CI, 1.30-1.88; p < 0.001).
Overall, 100-day cumulative incidence of acute GVHD and 4-year cumulative incidence of chronic GVHD were 29 6 2 and 21 6 2%, respectively. Transplantation of CBUs with two or more of six HLA mismatches was associated with increased risk of chronic GVHD (HR, 1.70; 95% CI, 1.05-2.78; p 5 0.033; Table 3 ). Relapse incidence (RI) was 27 6 2% at 4 years. Disease status was the only factor associated with RI in multivariate analysis (Table 3 ; HR, 0.68; 95% CI, 0.48-0.96; p 5 0.030 for patients transplanted in CR1). NRM was 16 6 2% at 100 days and 30 6 2% at 4 years. Diagnosis of AML and CMV-negative serology were both associated with decreased 100-day NRM in multivariate analysis (Table 3 ; HR, 0.56; 95% CI, 0.35-0.88; p 5 0.014; and HR, 0.58; 95% CI, 0.38-0.90; p 5 0.016, respectively).
The 4-year OSs in CBTs carried out with either concentrated or nonconcentrated CBUs were 46 6 3 and 43 6 3%, respectively (p 5 0.43; Fig. 2) . In multivariate analysis, factors associated with increased survival (both OS and LFS) were transplantation in children, in CR1, and diagnosis of AML (Table 3) .
DISCUSSION
This is a large-scale, retrospective registry analysis focusing on the clinical impact of the major variables associated to the banking of CBUs for allogeneic transplantation in an unrelated setting: namely, VR and CBU age at thawing. Such analysis had been previously reported in the form of internal analysis by the individual CBB. 4, 19, 20 Differences in CB banking were also analyzed within single CBT programs. 8 QC programs have been implemented to ensure the quality of CBUs. FACT (Foundation for Accreditation of Cellular Therapy)-NetCord and the AABB programs rely on a list of procedures to be followed by CBBs to provide bank accreditation through an "on-site" inspection process. In some countries, local accreditation systems of the banks are in place. The accreditation systems aim at standardizing all the banking steps with the final goal of achieving better quality and homogeneity in the banks' CBU inventory, therefore improving the clinical outcomes of CBT. 21 Nevertheless, selection of a CBU from an accredited bank is not currently mandatory. Indeed, it should be mentioned that most of the major banks have been operating for 10 years or longer and that their operating procedures may have changed through such an interval, possibly raising further biases. Therefore, the influence of banking on the clinical outcome needs to be investigated through the analysis of all major variables associated with the banking process, from collection to shipping, rather than those associated with the CBB itself. In this regard, it should be noted that the duration of the storage did not have any negative impact on the clinical outcome. Interestingly, the number of frozen TNCs is higher in volumereduced CBUs, due to the more recent attitude of CBBs to accept only high-quality units for storage. This large, retrospective study shows that current methods aimed at reducing the CBU volume before freezing do not affect the clinical outcome of the CBT, therefore providing evidence of a satisfactory validation and reproducibility of such techniques. Methods are based on the removal of components of the graft that do not influence the engraftment and immune recovery, such as plasma and RBCs. Keeping the latter in the graft (RBC-replete units) results in a higher frozen volume and probably in a higher content of PMNs, compared to RBC-depleted units. In fact, PMNs tend to sediment faster than mononuclear cells, having a higher probability to be removed together with the RBC pellet after centrifugation. A correction factor was proposed for CBUs manipulated by plasma depletion, 22 but this approach is still controversial. 23 We show
here that the outcome of transplants performed with CBU containing an adequate number of TNCs at freezing (!3 3 10 7 /kg recipient body weight) is not influenced by the reduction of the graft volume before cryopreservation. Interestingly, this result was confirmed with any concentration and any method used; we adopted 30 mL to discriminate between RBC-depleted and RBC-replete units, respectively. A difference in the PMN content is expected in the two subsets, possibly too small to significantly influence the engraftment speed when combined with the other graft-and patient-associated variables.
It must be stressed that results derived by any registry analysis can be biased and their generalization should be validated through prospective studies; however, our data collected through a large, bank-independent analysis suggest that the cryogenic space saved by a high-fold reduction of the CBU volume does not have any major negative clinical impact, thus encouraging this increasingly used practice.
As expected, all the selected CBUs were maintained in liquid nitrogen-based cryogenic systems. The current standards specifically require that the product is kept at a temperature lower than 21508C, thus using vapor-phase storage or mechanical freezers. 24 Concerns about the longterm storage of unrelated, allogeneic CBUs can probably account for the choice of the liquid phase for both the lower temperature and the longer maintenance of the optimal storage conditions even in the occurrence of inconveniences such as temporary lack of power or nitrogen supply. The major lack of standardization in the banking process was found in the product characterization and especially in the QC on a reference sample. This is an important issue also due to the current practice of transplant centers to include cell viability in the CBU selection process, when different units with similar cellular content and HLA matching are available for one patient. CD341 cell count at freezing is often lacking in the old units; furthermore, CD341 cell viability assessment in the thawed sample needs further standardization. Most correlations between CD341 content and engraftment were generated at the transplant center level on the thawed product at infusion, 25, 26 while the count at freezing was not a better engraftment predictor than TNCs. 27 In this retrospective analysis the viability of nucleated cells was assessed by different methods: a clear description of the method should be included on the unit report to enable the transplant center to perform a realistic evaluation of the QC result in the CBU selection process. Indeed, a cooperative effort in the bank's network should be devoted to improve the standardization of both characterization and QCs of the units exposed in the registries. An international network of CBBs, transplant scientific societies, and registries have contributed in the past 20 years to make unrelated CB transplantation a clinical option for many patients missing a suitable donor. The current challenge is to improve the quality of the worldwide inventory by focusing collection of CBUs targeted at ethnic minorities and larger units. Improving the characterization of the CBUs by further standardization of the banking process will go a long way in improving outcomes after transplantation of this graft source. Finally it should be kept in mind that, apart from the graft quality, other clinical factors such as age, disease status, and conditioning regimen must be considered in the evaluation of CB as a stem cell source for transplantation. 
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